Ashish Khanna - Aptinyx Chief Business Officer
Executive
Mr. Ashish Khanna is Chief Business Officer of the Company. Mr. Khanna has served as our Chief Business Officer since July 2015 and as our Chief Financial Officer since February 2018. He was previously Vice President of Corporationrationrate Development at Naurex and managed its financing and transaction efforts between 2010 and 2015, culminating in the company acquisition by Allergan plc. Prior to Naurex, Mr. Khanna served as Director of Business Development at Vanda Pharmaceuticals. He was formerly a member of the cardiology strategic marketing team at Cordis Corporationrationration, a Johnson Johnson company. Earlier, Mr. Khanna was a strategy consultant with the Palladium Group and with the Strategic Advisory Services practice of Ernst Young . He serves on the board of directors of the Illinois Biotechnology Innovation Organization since 2018.
| Age | 47 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 847 871 0377 |
| Web | https://www.aptinyx.com |
Aptinyx Management Efficiency
The company has return on total asset (ROA) of (0.5135) % which means that it has lost $0.5135 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3806) %, meaning that it created substantial loss on money invested by shareholders. Aptinyx's management efficiency ratios could be used to measure how well Aptinyx manages its routine affairs as well as how well it operates its assets and liabilities.Aptinyx currently holds 22.11 M in liabilities with Debt to Equity (D/E) ratio of 0.39, which is about average as compared to similar companies. Aptinyx has a current ratio of 15.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aptinyx's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Thomas Rollins | Assembly Biosciences | 69 | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| James Wang | Virax Biolabs Group | N/A | |
| Clement Monteil | Virax Biolabs Group | N/A | |
| Dr D | Aditxt Inc | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| MS MD | Aditxt Inc | N/A | |
| Amy CFA | Assembly Biosciences | N/A | |
| Philippe Sauvage | Nuvation Bio | 48 | |
| Anuj MD | Assembly Biosciences | 47 | |
| YuWaye MD | CytomX Therapeutics | 57 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| RN MBA | Transcode Therapeutics | N/A | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Andrew Taubman | Adial Pharmaceuticals | N/A | |
| Joel Yeung | Virax Biolabs Group | N/A | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
Management Performance
| Return On Equity | -1.38 | |||
| Return On Asset | -0.51 |
Aptinyx Leadership Team
Elected by the shareholders, the Aptinyx's board of directors comprises two types of representatives: Aptinyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptinyx. The board's role is to monitor Aptinyx's management team and ensure that shareholders' interests are well served. Aptinyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptinyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathryn King, VP Operations | ||
| Norbert Riedel, President CEO, Director | ||
| Patrick Flavin, Sr Relations | ||
| Molly Dir, VP HR | ||
| Ashish Khanna, Chief Business Officer | ||
| Harald MD, VP Affairs | ||
| Tim Noffke, VP Staff | ||
| MD BCh, Pres CEO |
Aptinyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aptinyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.38 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | (25.91 M) | |||
| Shares Outstanding | 67.72 M | |||
| Shares Owned By Insiders | 13.12 % | |||
| Shares Owned By Institutions | 42.96 % | |||
| Number Of Shares Shorted | 2.23 M | |||
| Price To Earning | (5.61) X | |||
| Price To Book | 0.33 X | |||
| Price To Sales | 45.33 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Aptinyx Stock
If you are still planning to invest in Aptinyx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aptinyx's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |